Literature DB >> 6345714

Antibodies to normal human melanocytes in vitiligo.

G K Naughton, M Eisinger, J C Bystryn.   

Abstract

Most patients with active vitiligo (82% of 61) have antibodies to antigens of normal human melanocytes that can be detected by specific immunoprecipitation of radioiodinated, detergent-soluble, melanocyte macromolecules. Such antibodies were present in only 12% of patients with melanoma and in none of 35 patients with nonpigmentary skin diseases. The antibodies were directed to a common antigen(s) on melanocytes that was not present on normal fibroblasts or keratinocytes. These observations suggest that vitiligo is an autoimmune disease mediated by antibodies to melanocyte-associated antigen(s).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345714      PMCID: PMC2187087          DOI: 10.1084/jem.158.1.246

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  Serum anti-tumour antibodies and auto-antibodies in vitiligo.

Authors:  H Woolfson; O A Finn; R M Mackie; A McQueen; R N MacSween
Journal:  Br J Dermatol       Date:  1975-04       Impact factor: 9.302

2.  [MELANIN ANTIBODIES IN VITILIGO].

Authors:  H LANGHOF; M FEUERSTEIN; G SCHABINSKI
Journal:  Hautarzt       Date:  1965-05       Impact factor: 0.751

3.  Human epidermal cell cultures: growth and differentiation in the absence of differentiation in the absence of dermal components or medium supplements.

Authors:  M Eisinger; J S Lee; J M Hefton; Z Darzynkiewicz; J W Chiao; E de Harven
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

4.  Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells.

Authors:  C Betterle; A Peserico; G Bersani
Journal:  Arch Dermatol       Date:  1979-03

5.  Exposed protein on the intact human erythrocyte.

Authors:  D R Phillips; M Morrison
Journal:  Biochemistry       Date:  1971-05-11       Impact factor: 3.162

6.  Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin.

Authors:  M Eisinger; O Marko
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Vitiligo. What is it? Is it important?

Authors:  A B Lerner; J J Nordlund
Journal:  JAMA       Date:  1978-03-20       Impact factor: 56.272

8.  Identification and purification of a Mr 75,000 cell surface human melanoma-associated antigen.

Authors:  J Heaney-Kieras; J C Bystryn
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

9.  Autoimmune vitiligo: detection of antibodies to melanin-producing cells.

Authors:  K C Hertz; L A Gazze; C H Kirkpatrick; S I Katz
Journal:  N Engl J Med       Date:  1977-09-22       Impact factor: 91.245

10.  Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis.

Authors:  N Howanitz; J L Nordlund; A B Lerner; J C Bystryn
Journal:  Arch Dermatol       Date:  1981-11
  10 in total
  31 in total

1.  Complementary expression of melanosomal antigens and constant expression of pigment-independent antigen during the evolution of melanocytic tumours.

Authors:  H Takahashi; P G Parsons; D Favier; M McEwan; G M Strutton; Y Akutsu; K Jimbow
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

3.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

4.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

5.  Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in vitro.

Authors:  N Puri; M Mojamdar; A Ramaiah
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

6.  Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.

Authors:  D R Vlock; J M Kirkwood
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Liver cell surface expression of the antigen reacting with liver-kidney microsomal antibody (LKM).

Authors:  M Lenzi; F B Bianchi; F Cassani; E Pisi
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

8.  L-Phenylalanine and UVA/sunlight for vitiligo.

Authors:  R H Cormane; A H Siddiqui
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

9.  Alopecia totalis and vitiligo in common variable immunodeficiency.

Authors:  G Spickett; A G Prentice; T Wallington; A D Webster; H Chapel
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

10.  Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Authors:  M Lotem; T Peretz; O Drize; Z Gimmon; D Ad El; R Weitzen; H Goldberg; I Ben David; D Prus; T Hamburger; E Shiloni
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.